Transplant center directory

Barnes-Jewish Hospital and St. Louis Children's Hospital are part of BJC Healthcare, one of the largest nonprofit health care organizations in the United States, and the Alvin J. Siteman Cancer Center is Missouri's only NCI-designated Comprehensive Cancer Center. Our program works closely with Washington University School of Medicine physicians and researchers, and we are committed to providing the highest quality care and to developing innovative treatments to improve patient survival and quality of life.

This center has been performing allogeneic transplants since 1982 and has been an NMDP/Be The Match transplant center since April 1991.

Barnes Jewish Hospital

This center's actual 1-year survival results are below the expected rate for this center.

The survival information we have for this center includes ONLY:

1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2019, 2020, 2021, and
2. Who had their transplant at a U.S. transplant center, and
3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 356 patients.

The actual 1-year survival of these patients is 62.6%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 66.2% and 75.2%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

Washington University/St Louis Children's Hospital

This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2019, 2020, 2021, and
2. Who had their transplant at a U.S. transplant center, and
3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 52 patients.

The actual 1-year survival of these patients is 84.6%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 76.7% and 94.8%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

All diseases

Number of transplants by age reported from January 1, 2021 to December 31st, 2022 (includes marrow, PBSC and cord blood)

Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.